overall CD patients 3 and more than 90% of patients with rectal involvement. 4 The management of PFCD is multidisciplinary, with intensive medical therapy associated to multiple surgical procedures. This usually results in significant physical and psychological impact in patients' lives. There are significant limitations of conventional medical treatment in PFCD (corticosteroids, immunosuppressants, and antibiotics). Fistula healing rates are low with this strategy and recurrence is frequent. 5 Some prospective studies have demonstrated the efficacy of biologics in controlling perianal fistulas in CD. Present et al., 6 in the first randomized controlled study with biologics for the treatment of fistulizing CD, demonstrated the effectiveness of infliximab (IFX) in closing abdominal and perianal fistulas. Sands et al., 7 in the ACCENT 2 study, demonstrated the better efficacy of IFX as compared to